Alan Tenaglia, MD
Cardiovascular Disease · Scottsdale, AZNPI 1215976550
Payments from drug & device makers
Across 194 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Abbott$823
- E.r. Squibb & Sons, L.L.C.$577
- Bardy Diagnostics, Inc.$345
- Pfizer$309
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$291
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,871100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 54 | $1,016 |
| Abbott | 15 | $823 |
| E.r. Squibb & Sons, L.L.C. | 9 | $577 |
| Bardy Diagnostics, Inc. | 9 | $345 |
| Pfizer | 19 | $309 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $291 |
| Amgen | 12 | $232 |
| Biosense Webster, Inc. | 1 | $198 |
| Impulse Dynamics (USA) Inc. | 2 | $169 |
| Heartflow, Inc. | 2 | $152 |
| Merck | 6 | $139 |
| Edwards Lifesciences | 5 | $138 |
| Novo Nordisk | 5 | $105 |
| Sanofi-aventis U.S. LLC | 6 | $102 |
| Amarin Pharma, Inc. | 1 | $87 |
| Baxter Healthcare | 3 | $64 |
| Cleerly, Inc. | 1 | $62 |
| Boston Scientific | 2 | $53 |
| Lexicon Pharmaceuticals, Inc. | 3 | $49 |
| Boehringer Ingelheim | 2 | $46 |
| Johnson & Johnson | 3 | $45 |
| Bridgebio Pharma, Inc. | 2 | $43 |
| Kestra Medical Technology Services, Inc. | 2 | $43 |
| AstraZeneca | 3 | $39 |
| Philips North America LLC | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $26 |
| Bayer | 1 | $25 |
| Astellas Pharma US Inc | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Itamar Medical Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,294 in reported general payments places this provider in the 60th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 734 | $857,688 |
| EntrestoSacubitril/Valsartan | 323 | $394,351 |
| JardianceEmpagliflozin | 183 | $156,360 |
| XareltoRivaroxaban | 106 | $140,922 |
| Repatha SureclickEvolocumab | 123 | $114,784 |
| FarxigaDapagliflozin Propanediol | 54 | $58,206 |
| Praluent PenAlirocumab | 46 | $44,091 |
| MultaqDronedarone Hcl | 16 | $38,566 |
| BrilintaTicagrelor | 39 | $33,697 |
| LivaloPitavastatin Calcium | 30 | $23,241 |
| Repatha SyringeEvolocumab | 15 | $20,642 |
| VascepaIcosapent Ethyl | 27 | $15,576 |
| NexletolBempedoic Acid | 24 | $13,589 |
| Metoprolol Succinate | 769 | $11,413 |
| Atorvastatin Calcium | 888 | $9,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $309 | $857,688734 claims |
| NovartisEntresto | $1,016 | $394,351323 claims |
| Boehringer IngelheimJardiance | $46 | $156,360183 claims |
| Johnson & JohnsonXarelto | $45 | $140,922106 claims |
| AstraZenecaFarxiga, Brilinta | $39 | $91,90393 claims |
| Sanofi-aventis U.S. LLCMultaq | $102 | $38,56616 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $14 | $23,24130 claims |
| Esperion Therapeutics, Inc.Nexletol | $15 | $13,58924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Scottsdale
- David RizikScottsdale$2.1M
- Krishnaswami VijayaraghavanScottsdale$927K
- Steven LesterScottsdale$336K
- William FreemanScottsdale$279K
- Paul UnderwoodScottsdale$259K
- Robert BurkeScottsdale$258K
- Imad KhaledScottsdale$252K
- Said AlsidawiScottsdale$222K
- Tasneem NaqviScottsdale$150K
- Philip GideonScottsdale$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.